N. Anthony Coles, M.D. Named to LabCorp(R) Board of Directors

BURLINGTON, N.C., Dec 07, 2010 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE:LH) today announced that N. Anthony Coles, M.D., has been elected to its Board of Directors, effective January 1, 2011. Dr. Coles is President and CEO of Onyx Pharmaceuticals, Inc.

LabCorp Successfully Completes Acquisition of Genzyme Genetics

BURLINGTON, N.C., Dec 01, 2010 (BUSINESS WIRE) -- Laboratory Corporation of America(R) Holdings (NYSE: LH) today announced the successful completion of its acquisition of Genzyme Genetics, a business unit of Genzyme Corp. (NASDAQ: GENZ), in an all cash transaction valued at $925 million.

LabCorp is Scheduled to Present at the 22nd Annual Piper Jaffray Health Care Conference

BURLINGTON, N.C., Nov 22, 2010 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the 22nd Annual Piper Jaffray Health Care Conference in New York City, NY.

LabCorp's Acquisition of Genzyme Genetics Clears Antitrust Review

BURLINGTON, N.C., Nov 18, 2010 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (NYSE: LH) today announced that it has received early termination from the Federal Trade Commission of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act,

LabCorp Prices $325 Million in 3.125% Senior Notes Due 2016 and $600 Million in 4.625% Senior Notes Due 2020

BURLINGTON, N.C., Nov 16, 2010 (BUSINESS WIRE) -- Laboratory Corporation of America Holdings (LabCorp) (NYSE: LH) announced today that it has priced its offering of $925 million in senior notes. The offering consists of two tranches: $325 million aggregate principal amount of 3.125% Senior Notes

LabCorp Announces Proposed Sale of up to $925 Million of Senior Notes

BURLINGTON, N.C., Nov 16, 2010 (BUSINESS WIRE) -- Laboratory Corporation of America Holdings (LabCorp) (NYSE: LH) announced today that it plans to offer, subject to market and other conditions, senior notes in an aggregate principal amount of up to $925 million (the "Notes").

LabCorp is Scheduled to Present at the Credit Suisse 2010 Annual Healthcare Conference

BURLINGTON, N.C., Nov 05, 2010 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the Credit Suisse 2010 Annual Healthcare Conference in Phoenix, AZ.

Laboratory Corporation of America(R) Holdings Announces 2010 Third Quarter Results

Company Highlights Revenue Growth of 7.7% and Adjusted EPS Growth of 20.5% BURLINGTON, N.C., Oct 21, 2010 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) today announced results for the quarter ended September 30, 2010.

Conversion Right Triggered for LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C., Oct 04, 2010 (BUSINESS WIRE) -- Laboratory Corporation of America Holdings (LabCorp) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C., Sep 13, 2010 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) announced today that for the period of September 12, 2010 to March 11, 2011, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the